We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
An implantable cardioverter-defibrillator but not amiodarone reduced risk for death in congestive heart failure.
- Authors
Corsello, Andrew
- Abstract
This article focuses on a study related to an implantable cardioverter-defibrillator for congestive heart failure. 70% of patients had New York Heart Association class II congestive heart failure (CHF) and 30% had class III CHF. 188 patients from the amiodarone and placebo groups crossed over to some form of implantable cardioverter-defibrillator (ICD) therapy. 259 patients in the ICD group received shocks from their device for any cause. Fewer patients who received ICD died from any cause than did those who received placebo. The Sudden Cardiac Death (SCD)-Heart Failure Trial (HeFT) trial provides evidence for prophylactic use of ICDs. The historical importance of SCD-HeFT and its effect on clinical practice must account for the trial's immediate influence on Medicare guidelines.
- Subjects
AMIODARONE; BENZOFURAN; PLACEBOS; CLINICAL medicine; HEALTH policy; MEDICARE
- Publication
ACP Journal Club, 2005, Vol 143, Issue 1, p17
- ISSN
1056-8751
- Publication type
Article
- DOI
10.7326/acpjc-2005-143-1-006